Molecular and Genetic Diagnosis and Targeted Therapy of Myeloproliferative Neoplasms (2nd Edition)

Dear Colleagues,

This Special Issue is the second edition of a previous issue on “Molecular and Genetic Diagnosis and Targeted Therapy of Myeloproliferative Neoplasms” (https://www.mdpi.com/journal/cancers/special_issues/Y70WEC829B).

Myeloproliferative neoplasms (MPNs), including chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), and MPN NOS, are among the most common myeloid neoplasms. Their treatments and their prognosis are different. However, they can show overlapping clinical presentations and are sometimes difficult to distinguish from each other. Therefore, it is critical to perform correct diagnosis and stratification on patients with MPNs. With the advancement of new technologies such as NextGen sequencing, there has been rapid progress in understanding the pathogenesis, diagnosis, prognosis, and targeted therapy of MPNs. The purpose of this Special Issue is to present current advancements in the diagnosis and prognosis prediction of MPNs. This Special Issue welcomes reviews as well as original research articles, which should be submitted by 15 May 2026.

Dr. Jinming Song
Dr. Ling Zhang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.